CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-11-25): FDA approves oral simeprevir (Olysio) for hepatitis C

Regulatory

FDA approves oral simeprevir (Olysio) for hepatitis C

Last Updated: 2013-11-25 13:40:21 -0400 (Reuters Health)

(Reuters) - U.S. regulators late Friday approved Johnson & Johnson's oral protease inhibitor Olysio (simeprevir) for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen.

Efficacy was demonstrated in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis, the company said.

Olysio may benefit patients with chronic hepatitis C, including those who are treatment naive or who have failed prior interferon-based therapy.

Hepatitis C affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer.

For treatment-naive and prior-relapser patients, a fixed treatment regimen of 12 weeks of Olysio combined with 24 weeks of pegylated interferon and ribavirin is recommended, the company notes. For prior partial- and null-responder patients, a treatment regimen of 12 weeks of Olysio combined with 48 weeks of pegylated interferon and ribavirin is recommended.

"Given the complexity of the condition, Olysio was studied in a number of different patient populations, including individuals who have relapsed or failed to respond to previous treatments," Dr. Douglas Dieterich, Professor of Medicine in the Division of Liver Diseases, Mount Sinai School of Medicine, and Olysio clinical trial investigator, said in a company statement.

He called the approval of Olysio "an important milestone for people living with chronic hepatitis C as it means that patients have a new treatment option with the potential to cure this challenging disease."

Olysio is a member of the same class of drugs as Merck & Co's Victrelis (boceprevir) and Vertex Pharmaceuticals' Incivek (telaprevir). The FDA approved both those drugs in 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.